ArticleMolecular psychiatry2012
Another view of the history of antipsychotic drug discovery and development.
Article in Molecular psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Review
- The 3q OncogeneInternational journal of molecular sciences · 2023Article
- The Difficult Path to the Discovery of Novel Treatments in Psychiatric Disorders.Advances in neurobiology · 2023Article
- Seventy Years of Treating Delusional Disorder with Antipsychotics: A Historical Perspective.Biomedicines · 2022Review
- The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets.NPJ genomic medicine · 2022Review
- Involvement of anti-inflammatory, antioxidant, and BDNF up-regulating properties in the antipsychotic-like effect of the essential oil of Alpinia zerumbet in mice: a comparative study with olanzapine.Metabolic brain disease · 2021Article
- Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder.The American journal of psychiatry · 2021Review
- Effects of Doxycycline in Swiss Mice Predictive Models of Schizophrenia.Neurotoxicity research · 2020Article
- Investigation of betaine as a novel psychotherapeutic for schizophrenia.EBioMedicine · 2019Article
- Modulation of extrasynaptic GABANature communications · 2019Article
- Documentation of antipsychotic-related adverse drug reactions: An educational intervention.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2019Article
- How Neuroscience Is Informing Treatments: Ethical Issues.Focus (American Psychiatric Publishing) · 2019Article
- Translational Significance of Selective Estrogen Receptor Modulators in Psychiatric Disorders.International journal of endocrinology · 2018Review
- Leveraging genome characteristics to improve gene discovery for putamen subcortical brain structure.Scientific reports · 2017Article
- Identification of SEC62 as a potential marker for 3q amplification and cellular migration in dysplastic cervical lesions.BMC cancer · 2016Article
- The impact of second-generation antipsychotic adherence on positive and negative symptoms in recent-onset schizophrenia.Schizophrenia research · 2014Article
- Patterns of antipsychotic prescription to patients with schizophrenia in Korea: results from the health insurance review & assessment service-national patient sample.Journal of Korean medical science · 2014Article
- Article
- A case of paranoid schizophrenia and severe antipsychotic-induced Parkinson's disorder treated with a combination of olanzapine and lurasidone.Innovations in clinical neuroscience · 2013Article
- Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers.BMC psychiatry · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chlorpromazine initiated effective pharmacotherapy for schizophrenia 60 years ago. This discovery initiated or stimulated key developments in the field of psychiatry. Nonetheless, advances in pharmacotherapy of schizophrenia have been modest. Psychosis remains the primary aspect of psychopathology addressed, and core pathologies such as cognition and negative symptom remain unmet therapeutic challenges. New clinical and basic neuroscience paradigms may guide the near future and provide a more heuristic construct for novel and innovative discovery.
Indexed as
Identifiers
22889923What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.